RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vanda Pharmaceuticals Stock

Vanda Pharmaceuticals P/S 2024

Vanda Pharmaceuticals P/S

1.43

Ticker

VNDA

ISIN

US9216591084

WKN

A0JJT3

As of Sep 19, 2024, Vanda Pharmaceuticals's P/S ratio stood at 1.43, a -18.75% change from the 1.76 P/S ratio recorded in the previous year.

The Vanda Pharmaceuticals P/S history

Vanda Pharmaceuticals Aktienanalyse

What does Vanda Pharmaceuticals do?

Vanda Pharmaceuticals Inc is a US biotechnology company specializing in the development and marketing of innovative therapies for neurological, psychiatric, and cardiovascular diseases. It was founded in 2002 by Mihael H. Polymeropoulos, who previously worked as a senior researcher at the genetic research company Novartis. Vanda Pharmaceuticals is based in Washington D.C. The company's business model focuses on developing and bringing to market medicines for rare diseases. It collaborates closely with clinics and research institutes to tailor innovative therapies and medications to the specific needs of patients. Vanda Pharmaceuticals operates in various areas, including neurology, psychiatry, and cardiology. In neurology, the company focuses on researching and developing therapies for rare diseases such as isolated sleeplessness syndrome and delayed sleep phase syndrome. In psychiatry, Vanda Pharmaceuticals has brought several medications to market for the treatment of schizophrenia, bipolar disorder, and depression. The medication Fanapt, in particular, has become a successful schizophrenia medication and has already been approved by the US FDA. In cardiology, Vanda Pharmaceuticals is working on the development of medications for the treatment of cardiovascular diseases such as heart failure and high blood pressure. One of Vanda Pharmaceuticals' most innovative therapy forms is chronotherapy, which involves timing the intake of certain medications to the body's natural circadian rhythm. The goal of chronotherapy is to maximize treatment effectiveness while minimizing side effects. An example of Vanda Pharmaceuticals' successes is the aforementioned medication Fanapt, which was approved by the FDA in 2009 and is distributed worldwide. Clinical studies have shown that Fanapt is safe and effective in the treatment of schizophrenia. The high expectations for the medication have led to Vanda Pharmaceuticals' listing on the NASDAQ and the company having a market value of several hundred million dollars. In conclusion, Vanda Pharmaceuticals is an innovative biotechnology company specializing in the research and development of therapies for rare diseases. With the successful introduction of medications like Fanapt, the company has established itself as an important player in the American and international markets. Vanda Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Vanda Pharmaceuticals's P/S Ratio

Vanda Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Vanda Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Vanda Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Vanda Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Vanda Pharmaceuticals stock

What is the price-to-earnings ratio of Vanda Pharmaceuticals?

The price-earnings ratio of Vanda Pharmaceuticals is currently 1.43.

How has the price-earnings ratio of Vanda Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Vanda Pharmaceuticals has increased by -18.75% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Vanda Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Vanda Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Vanda Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Vanda Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Vanda Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Vanda Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Vanda Pharmaceuticals?

Some factors that influence the price-earnings ratio of Vanda Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Vanda Pharmaceuticals pay?

Over the past 12 months, Vanda Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vanda Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vanda Pharmaceuticals?

The current dividend yield of Vanda Pharmaceuticals is .

When does Vanda Pharmaceuticals pay dividends?

Vanda Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vanda Pharmaceuticals?

Vanda Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vanda Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vanda Pharmaceuticals located?

Vanda Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vanda Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vanda Pharmaceuticals from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Vanda Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Vanda Pharmaceuticals in the year 2023?

In the year 2023, Vanda Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vanda Pharmaceuticals pay out the dividend?

The dividends of Vanda Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Vanda Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Vanda Pharmaceuticals

Our stock analysis for Vanda Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vanda Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.